Welcome to our dedicated page for Qilian International Holding Group Ltd. Ordinary Shares SEC filings (Ticker: QLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Qilian International Holding Group Ltd (historically Nasdaq: QLI, now filing as BGM Group Ltd) aggregates the company’s regulatory disclosures made to the U.S. Securities and Exchange Commission. These filings include Form 20-F annual reports and Form 6-K current reports that provide insight into the company’s financial condition, operating performance and corporate actions over time.
For this issuer, filings are particularly relevant to investors following pharmaceutical preparation manufacturing and related chemical products. In its reports, the company discusses revenue and cost trends across product categories such as licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings and fertilizers. Management’s discussion and analysis, furnished in exhibits to Form 6-K, explains how factors like raw material prices, exchange rates and market demand affect gross margins, income from operations and cash flows.
More recent filings under the BGM Group Ltd name highlight corporate developments beyond the traditional pharmaceutical and chemical businesses. A June 2025 Form 6-K describes the completion of a strategic acquisition of HM Management Company Limited, with consideration paid in Class A ordinary shares, and states that the company aims to expand its AI application portfolio and integrate resources from AI insurance and AI mobility businesses. An August 2025 Form 6-K details an acting in concert agreement between major shareholders, outlining arrangements intended to maintain a stable shareholder structure and control of the company.
On Stock Titan, these filings are updated as they are posted to the EDGAR system. AI-powered tools can help readers navigate lengthy documents such as annual reports on Form 20-F or multi-exhibit Form 6-K submissions by highlighting key points on segment performance, liquidity, capital structure, share issuances and governance agreements. Users interested in historical QLI information or current BGM Group Ltd disclosures can review the underlying filings and use AI-generated summaries to better understand the implications of each report.
Group Ltd reports that director Furong Cao and shareholder Zhanchang Xin have entered into an acting in concert agreement dated July 5, 2025. Ms. Cao, directly and through Ahanzhai Development Limited, holds 9,800,000 Class B ordinary shares, representing approximately 4.9% of outstanding ordinary shares and 44.9% of aggregate voting power. Mr. Xin, directly and through LX Management Company Limited, holds 10,200,000 Class B ordinary shares, representing approximately 5.1% of outstanding ordinary shares and 46.8% of aggregate voting power. Under the agreement, they intend to act in concert on all shareholder and board matters, voting together when they reach a unanimous view and voting against if they disagree. As a result, each can be deemed a beneficial owner of about 10.0% of outstanding ordinary shares and 91.7% of aggregate voting power, concentrating effective control while the agreement remains in force until terminated.
FAQ
What is the current stock price of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?
What is the market cap of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?
